These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10496290)

  • 1. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias.
    Pact V; Giduz T
    Neurology; 1999 Sep; 53(5):1154. PubMed ID: 10496290
    [No Abstract]   [Full Text] [Related]  

  • 2. Mirtazapine in L-dopa-induced dyskinesias.
    Meco G; Fabrizio E; Di Rezze S; Alessandri A; Pratesi L
    Clin Neuropharmacol; 2003; 26(4):179-81. PubMed ID: 12897636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
    Manson AJ; Iakovidou E; Lees AJ
    Mov Disord; 2000 Mar; 15(2):336-7. PubMed ID: 10752589
    [No Abstract]   [Full Text] [Related]  

  • 4. Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.
    Espay AJ; Lang AE
    JAMA Neurol; 2017 Jun; 74(6):633-634. PubMed ID: 28459962
    [No Abstract]   [Full Text] [Related]  

  • 5. Mirtazapine in Parkinsonian tremor.
    Gordon PH; Pullman SL; Louis ED; Frucht SJ; Fahn S
    Parkinsonism Relat Disord; 2002 Dec; 9(2):125-6. PubMed ID: 12473405
    [No Abstract]   [Full Text] [Related]  

  • 6. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
    Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two iatrogenic dyskinesias.
    Karson CN; Jeste DV; LeWitt PA; Wyatt RJ
    Am J Psychiatry; 1983 Nov; 140(11):1504-6. PubMed ID: 6137963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mirtazapine in the pharmacotherapy of depression.
    J Clin Psychiatry; 2000 Aug; 61(8):609-16. PubMed ID: 10982209
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease.
    Caparros-Lefebvre D; Blond S; Vermersch P; Pécheux N; Guieu JD; Petit H
    J Neurol Neurosurg Psychiatry; 1993 Mar; 56(3):268-73. PubMed ID: 8459243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced dyskinesia and thalamotomy.
    Narabayashi H; Yokochi F; Nakajima Y
    J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):831-9. PubMed ID: 6381653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirtazapine in bupropion-induced dyskinesias: a case report.
    Kohen I; Sarcevic A
    Mov Disord; 2006 Apr; 21(4):584-5. PubMed ID: 16511872
    [No Abstract]   [Full Text] [Related]  

  • 14. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
    Kostic V; Przedborski S; Flaster E; Sternic N
    Neurology; 1991 Feb; 41(2 ( Pt 1)):202-5. PubMed ID: 1992362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Turjanski N; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 May; 55(5):413. PubMed ID: 1602321
    [No Abstract]   [Full Text] [Related]  

  • 16. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
    Arlazoroff A; Flechtir S; Goldexberg E; Bleicher Z; Barber Y
    Harefuah; 1985 Mar; 108(5):227-9. PubMed ID: 4007677
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
    Buongiorno M; Antonelli F; Cámara A; Puente V; de Fabregues-Nebot O; Hernandez-Vara J; Calopa M; Pascual-Sedano B; Campolongo A; Valldeoriola F; Tolosa E; Kulisevsky J; Martí MJ
    Parkinsonism Relat Disord; 2015 Aug; 21(8):871-6. PubMed ID: 26003410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
    Kipfer S; Stephan MA; Schüpbach WM; Ballinari P; Kaelin-Lang A
    Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex.
    Caparros-Lefebvre D; Blond S; Feltin MP; Pollak P; Benabid AL
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):308-14. PubMed ID: 10449551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.